| __timestamp | Verona Pharma plc | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1802274 | 1499100000 |
| Thursday, January 1, 2015 | 2512761 | 1923500000 |
| Friday, January 1, 2016 | 2894488 | 2351400000 |
| Sunday, January 1, 2017 | 8096274 | 2564000000 |
| Monday, January 1, 2018 | 7985229 | 2397300000 |
| Tuesday, January 1, 2019 | 8994597 | 2503400000 |
| Wednesday, January 1, 2020 | 29772000 | 3344600000 |
| Friday, January 1, 2021 | 33907000 | 4529200000 |
| Saturday, January 1, 2022 | 26579000 | 4179100000 |
| Sunday, January 1, 2023 | 49868547 | 4650100000 |
Unleashing the power of data
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares the SG&A efficiency of Viatris Inc. and Verona Pharma plc from 2014 to 2023.
Viatris Inc. has consistently increased its SG&A expenses, peaking at approximately $4.65 billion in 2023. This represents a growth of over 200% from 2014, reflecting its expansive operations and strategic investments.
In contrast, Verona Pharma plc's SG&A expenses surged by over 2,600% during the same period, reaching nearly $50 million in 2023. This dramatic increase highlights its aggressive growth strategy and market expansion efforts.
While Viatris Inc. demonstrates steady growth, Verona Pharma plc's rapid increase in SG&A expenses underscores its ambitious market positioning.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Who Optimizes SG&A Costs Better? AbbVie Inc. or Verona Pharma plc
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Verona Pharma plc and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights